Molecular insights into HR+/HER2+ early-stage breast cancer: Neoadjuvant therapy responses by MammaPrint and BluePrint genomic subtypes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results